News & Updates
Filter by Specialty:
NATALEE update: Ribociclib + NSAI well tolerated
Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).
NATALEE update: Ribociclib + NSAI well tolerated
12 Jul 2024
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
12 Jul 2024
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
10 Jul 2024
Nomogram predicts acute radiation enteritis in cervical cancer
A nomogram model displays a decent performance in predicting grade ≥2 acute radiation enteritis (ARE) among patients with cervical cancer receiving concurrent chemoradiotherapy, a study has shown.
Nomogram predicts acute radiation enteritis in cervical cancer
10 Jul 2024
Bulky tumours in PCNSL tied to high local treatment failure
Systemic and intrathecal therapies are necessary for local control in patients with primary central nervous system lymphoma (PCNSL), but bulky tumours remain a problem, according to a study.